Innate and adaptive immune cells work in concert to generate efficient protection at mucosal surface. Vaginal mucosa is an epithelial tissue that contains innate and adaptive immune effector cells. Our previous studies demonstrated that vaginal administration of Cholera toxin -based vaccines generate antigen-specific CD8 T cells through the stimulation of local dendritic cells (DC). Innate lymphoid cells (ILC) are a group of lymphocytes localized in epithelial tissues that have important immune functions against pathogens and in tissue homeostasis. Their contribution to vaccine-induced mucosal T cell responses is an important issue for the design of protective vaccines. We report here that the vaginal mucosa contains a heterogeneous population of NKp46 + ILC that includes conventional NK cells and ILC1-like cells. We show that vaginal NKp46 + ILC dampen vaccine-induced CD8 T cell responses generated after local immunization. Indeed, in vivo depletion of NKp46 + ILC with anti-NK1.1 antibody or NKG2D blockade increases the magnitude of vaginal OVA-specific CD8 T cells. Furthermore, such treatments also increase the number of DC in the vagina. NKG2D ligands being expressed by vaginal DC but not by CD8 T cells, these results support that NKp46 + ILC limit mucosal CD8 T cell responses indirectly through the NKG2D-dependent elimination of vaginal DC. Our data reveal an unappreciated role of NKp46 + ILC in the regulation of mucosal CD8 T cell responses.
Introduction
The establishment of protective immunity at the entry site of sexually transmitted pathogens involves long-lasting tissue-associated memory T and B lymphocytes and is required to efficiently block the systemic spreading of those pathogens [1] . Genital protective B and T cell immunity is better achieved by mucosal rather than by parenteral immunization and antigens need to be admixed with appropriate adjuvants to develop efficient mucosal vaccines. A better understanding of the cellular mechanisms induced after intravaginal vaccination may help optimizing vaccines against sexually transmitted infection [2] .
The Vibrio cholerae toxin (CT) is a potent mucosal adjuvant widely used to understand the cellular and molecular events induced by mucosal immunization [3, 4] . CT has an AB5 structure composed of two distinct subunits: a single toxic A subunit (CTA) and a nontoxic homopentameric B subunit (CTB). CTB has a strong affinity for GM1 gangliosides that are present on all mammalian nucleated cells and are responsible for the anchor of the toxin onto host cells. CTB, which can be produced independently of the CTA moiety, constitutes an efficient antigen-delivery system for covalently linked proteins and polysaccharides [5] . We have shown that the intravaginal or the sublingual application of antigens conjugated to CTB and coadministered with CT induces antigen-specific IgA antibody secreting cells (ASCs) and cytotoxic CD8 T cells in the female genital tract [6] [7] [8] [9] . Moreover, the covalent linking of antigens to CTB is mandatory to favor their processing by mucosa derived dendritic cells (DC) and their delivery into the MHC class I pathway, thus leading to the generation of cytotoxic CD8 T cell responses [6, 10] . Nevertheless, the contribution of other innate leukocytes present at mucosal sites in the regulation of those responses remains to be explored.
Innate lymphoid cells (ILC) are a family of specialized lymphocytes of the innate immune system preferentially localized in epithelial tissues (intestine, skin, lung, uterus). They serve as an early source of cytokines to regulate mucosal immune responses but also to ensure tissue repair and tissue homeostasis [11] . ILC family comprises the well-described conventional cytotoxic natural killer cells (NK cells) that patrol lymphoid and non-lymphoid organs to discriminate and eliminate stressed cells (i.e. infected and tumor cells) as well as other ILC subsets. The ILC population shares expression of cell surface markers such as the IL-7 receptor-α (CD127) or IL-2 receptor-α (CD25) but they are distinct in terms of cytokine production: group 1 ILC (ILC1) produce interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α); group 2 ILC (ILC2) produce IL-5 and IL-13 and group 3 ILC (ILC3, that include lymphoid tissue inducer cells) produce IL-17 and IL-22 [12] [13] [14] . NKp46 was originally used to identify NK cells as it is expressed from early to late stages of NK cell differentiation [15] . This holds true in lymphoid organs but not in non lymphoid tissues where NKp46 also identifies some ILC1 and ILC3 subsets [13, 16, 17] . Moreover, ILC subsets are also defined on the basis of their differential requirements for transcription factors (TF) involved in their development and/or survival. Whereas NK cells required both T-bet and Eomes (Eomesodermine), ILC1 need only T-bet for their development. On the other hand, the TF GATA3 and RORα are necessary for ILC2 maintenance and RORγt is indispensable for all ILC3 subsets development [18, 19] .
It remains unknown whether the vaginal mucosa contains these recently described ILC subsets and only very few studies focused on the contribution of conventional NK cells in vaginal immunity. In NK cell deficient IL15 -/-and RAG-2 -/-/ γc -/-mice, intravaginal infection with Herpes Simplex Virus 2 (HSV 2) resulted in impaired innate immune response [20] . Moreover, depletion of NK1.1 + NK cells in the vaginal tissue of wild type C57BL/6 mice using the depleting anti-NK1.1 antibody resulted in increased sensitivity of these mice to vaginal HSV 2 infection [21] . NK1.1 is also expressed by the ILC1 subset in mice [18, 22] 
Material and Methods

Animals
Six to ten weeks-old female C57BL/6 mice were purchased from Charles River Laboratories (France).
Ethics statement
Animals were housed in isolators under pathogen-free conditions according to institutional guidelines. Anesthesia was performed using Ketamine and Xylazine to minimize suffering. Experiments were approved by an ethical committee for animal experimentation: Centre National de Reflexion Ethique sur l'Experimentation Animal: reference # CIEPAL n°NCE/ 2015-220.
Synthesis of cholera toxin-based vaccine
Cholera toxin (CT) was obtained from List Biologicals Laboratories (USA) and recombinant CTB from Crucell AB (Sweden). Albumin Chicken Egg (ovalbumin, OVA Grade VII, SigmaAldrich, France) was conjugated to CTB as described earlier [6] . 
Immunizations and injections of antibodies
Cell preparation
Vaginas from PBS-perfused mice were excised and cells dispersed by collagenase A (1mg/mL) and DNase I (0,2mg/mL) (Roche Diagnostics) treatment at 37°C for 20 minutes. Spleen and GLN cells were processed similarly to ensure that enzymatic treatment does not alter the surface expression of markers analyzed and the functions of cells. Small intestine NKp46 ILC were prepared as previously described [16] . Dendritic cells were purified from GLN and vaginas as previously described [6] . 
Immunofluorescence
Vagina mucosa and spleen were densified in a 30% sucrose solution, embedded in Shandon Cryomatrix ™ (ThermoElectron corp.) and frozen in a bath of isopentane cooled on dry ice. Tissue sections (7μm) were fixed in cold acetone and then saturated in PBS containing 0.1% Triton X-100, 0.05% tween 20, 2% mouse serum and 10% normal donkey serum. Mouse NKp46 and CD3ε stainings were performed using polyclonal goat anti-mouse NKp46 serum (R&D Systems) and monoclonal hamster anti-mouse CD3 antibody (2C11, BD Biosciences) after overnight incubation at 4°C. The day after, slides were incubated with Alexa594-conjugated donkey anti-goat antibody (Molecular Probes) to detect the NKp46 staining. After washes in PBS, slides were again saturated in PBS containing 0.1% Triton X-100, 0.05% tween 20, 2% mouse serum and 10% normal goat serum and incubated with Alexa488-conjugated goat antihamster antibody (Molecular Probes) to detect the CD3 staining. Slides were dried, mounted with Prolong Gold containing DAPI to stain nucleus and examined under Zeiss LSM 710 confocal microscope (Zeiss). Image processing was performed with Zeiss Zen and LSM softwares.
Functional assays
Cells from spleen, GLN, liver, small intestine and vaginas were plated for 4h at 37°C in U-bottom 96 well plates and incubated with either PMA (200 ng/mL, Sigma-Aldrich) and ionomycin (0.5 μg/mL, Sigma-Aldrich) or mouse IL-12 (20 ng/mL, R&D Systems) and mouse IL-18 (5 ng/ mL, MBL) or in the presence of YAC-1 tumor target cells at a 1:1 ratio or mouse IL-23 (20ng/ ml) and mouse IL1β (20ng/ml). In addition, cells were incubated for 4h in high-affinity Immulon flat-bottom 96 well plates coated with 25 μg/mL of anti-mouse NK1.1 or anti-mouse IgG1 mAb. NK cell degranulation was assessed after CD107a staining and IFN-γ production evaluated in presence of monensin and brefeldin A (BD Biosciences).
Statistics
Statistical analyses were carried out with Graphpad Prism software version 6.0 (GraphPad Prism, USA). Pairwise multiple comparisons of experimental groups were performed using the non parametric Mann-Whitney U test.
Results
Characterization of NKp46 + ILC in the mouse vagina
While conventional NK cells and others ILC subsets were recently identified in various epithelial tissues, very little is known about the presence of these innate lymphoid cells in the vaginal tissue. We first identified a consistent proportion of NKp46 + CD3 -cells among CD45 + leukocytes in the vagina of naive C57BL/6 mice. These cells were more frequent among leukocytes of vagina (4.1 ± 0.4%) than among those of spleen (2.8 ± 0.2%), those of genital draining lymph nodes (GLN) (0.6 ± 0.1%) and those of small intestine (0.28 ± 0.05%) (Fig 1A left panel) . (Fig 2A and 2B ). This Eomes -population specifically expressed CD49a
but not CD49b, thus resembling the ILC1 subset previously identified in liver and intestine ( Fig 2B) (Fig 3B) . In addition, upon crosslinking of the activating receptor NKR-P1C 
NKp46 + ILC limit vaginal CD8 T cell numbers generated by local immunization
Next, we sought to evaluate the contribution of NKp46 + ILC on vaginal CD8 T cell responses induced by local vaccination. We used a well-characterized subunit vaccine composed of ovalbumin covalently linked to CTB and co-administered with CT (CTBOVA+CT called hereafter the vaccine) that generates vaginal OVA-specific CD8 T cells [6] . Female C57BL/6 mice were immunized at days 0, 14 and 21 by vaginal route with the vaccine (Fig 4A) . The frequency of OVA-specific CD8 T cells was monitored 7 days after the last immunization in the vaginal mucosa and in the GLN. (Fig 4E) . In GLN, we also observed a 3.7 fold increase in the number of OVA-specific CD8 T cells (anti NK1.1: 61 260 ± 10 200 vs. IC: 16 500 ± 2 190). The frequency and numbers of non specific CD8 T cells as well as the frequency of IFN-γ producing OVA-specific CD8 T cells were not affected by the depletion of NK cells in the vagina and in the GLN (Fig 4F and data not shown) . These results indicate that NKp46 + ILC negatively regulate the pool of vaginal antigen-specific CD8 T cells induced upon local immunization without affecting their effector functions.
The NKG2D/NKG2D ligand interaction is involved in the regulation of vaccine-induced CD8 T cells after vaginal immunization NK cells were already described to limit effector and/or memory CD8 T cell responses in mouse models of LCMV infection or systemic immunization by a mechanism involving the activating receptor NKG2D [24, 25] . As vaginal NKp46 + ILC homogeneously expressed NKG2D (Fig 2A) , we then addressed its contribution in the regulation of vaginal CD8 T cell responses. C57BL/6 mice were treated with the blocking anti-NKG2D mAb (clone CX5) throughout the immunization protocol (Fig 4A) . This treatment did not affect the numbers of NKp46 + CD3 -cells in vagina and in GLN (Fig 4B and 4C ). Similarly to anti-NK1.1 treatment, NKG2D blockade significantly increased the number of OVA-specific CD8 T cells by 8 fold in the vagina and by 4.4 fold in GLN but did not affect IFN-γ production by OVA-specific CD8 T cells (Fig 4E and 4F ). Upon activation, it was previously shown that CD8 T cells can express NKG2D and NKG2D ligands such as Rae1 [26, 27] . Nevertheless, in our vaccination model, antigen-specific CD8 T cells did not express NKG2D or its ligand Rae1, excluding their NKG2D-dependent elimination directly by vaginal NKp46 + ILC or by NKG2D + CD8 T cells (Fig 5A) . Consequently, this suggested that vaginal NKp46 + ILC control CD8 T cell effectors indirectly after local vaccination. We next measured the expression of NKG2D ligands on vaginal dendritic cells as they are responsible for the generation of OVA-specific CD8 cells after local vaccination with the vaccine [6, 8] . Vaginal and GLN dendritic cells from immunized and control mice expressed substantial levels of the NKG2D ligands Rae1 and MULT1 whereas T cells did not ( Fig 5B and S4 Fig), 
Discussion
In this study, we characterize NKp46 + CD3 -ILC in the mouse vagina and show that this subset contains conventional Eomes + NK cells and Eomes -ILC1-like cells. Our data demonstrate that NKp46 + CD3 -ILC dampen vaginal CD8 T cell response to a local vaccine by an indirect NKG2D-dependent mechanism affecting numbers of vaginal dendritic cells. The ILC1 family includes the well-described conventional NK cells and ILC1 subsets recently identified in liver, intestine, skin, thymus and uterus [22, [28] [29] [30] [31] .They are closely related as they express the transcription factor T-bet, NK cell receptors such as NKp46, NKG2D and NK1.1 and produce IFN-γ. Conventional NK cells and subsets of ILC1 were first discriminated on the basis of different functional properties, NK cells being "cytotoxic" cells while ILC1 were rather "helper-like" cytokine producers. Subsets of ILC1 are also described to be endowed with cytotoxic properties via TRAIL or indirectly via secretion of TNF-α or IFN-γ [18, 32] . Consequently, Serafini et al., proposed to distinguish conventional NK and ILC subsets on the basis of Eomes expression with conventional NK being Eomes + and other ILC being Eomes - [18] . In the mouse vagina, we were able to identify conventional NK cells and ILC1-like cells. To our knowledge, this is the first characterization of conventional NK and ILC1 in such epithelial tissue. Nevertheless, we cannot rule out the possibility that vaginal NKp46 + Eomes -cells also include a subset of ex-ROR-γt ILC3 that differentiated into ILC1 by downregulation of RORγt and upregulation of T-bet [29, [33] [34] [35] . Further fate mapping experiments will be necessary to fully characterize mouse vaginal ILC. Vaginal ILC1 do not share all the features of liver ILC1, as they do not express TRAIL and do not produce TNF-α after in vitro stimulation. This suggests that the vaginal epithelial environment favors the emergence of a peculiar ILC1 subset. Comparative gene expression analyzes may help to fully characterize this new subset of ILC1 as well as to decipher the molecular events involved in the muco-epithelial imprinting of this subset of ILC1.
Vaginal Eomes + NK cells have a higher frequency of the immature CD11b -CD27 + subset as well as a lower expression of markers associated with NK cell maturation (CD49b and CD43) than splenic Eomes + NK cells [36, 37] . The higher frequency of immature Eomes + NK cells in the vagina can explain their lower effector functions after in vitro stimulation. These results are consistent with other studies that have demonstrated that NK cells from skin and gut exhibit lower effector functions than NK cells from secondary lymphoid organs [16, 17, 38] . Altogether, this suggests that the naturally tolerogenic environment of epithelia controls inappropriate NK cell functions and reactivity in steady conditions. Many studies have shown that NK cells impair T cell responses after systemic immunization or viral infection [39, 40] . Several mechanisms whereby NK cells regulate T cell responses were reported including engagement of the activating receptor NKG2D, TRAIL-dependent apoptosis, or cytokine production by NK cells [25, 37, [41] [42] [43] [44] [45] [46] [47] . Our study extends these observations to the vaginal compartment and indicates that vaginal secretes cytokines such as TNF-α, IFN-γ and IL-2 upon in vitro or in vivo stimulation and also expresses NKG2D and TRAIL [28, 48, 49] . In the intestine, subsets of ILC1 are also cytokine producers (IFN-γ and TNF-α) after in vitro stimulation with IL-12 + IL-15 or IL-12+ IL-18 or after mucosal infection [22, 29, 50] .They can also also degranulate after in vitro stimulation in the presence of tumor cell line [22] . [32] . More, IFN-γ producing ILC1 confer protection against intestinal Salmonella enterica and Toxoplasma gondii infection [29, 35] . NKG2D or TRAIL receptors have been involved in the lysis of activated CD4, CD8 T cells or DC [24, 49, 54] . Our data suggest that local NKp46 + ILC shape vaginal CD8 T cell responses through a NKG2D-dependent mechanism regulating DC numbers. The observation that vaginal ILC1-like cells cannot degranulate in response to various stimuli in vitro contrary to conventional NK cells strongly suggest that conventional NK cells rather than ILC1 dampen vaginal CD8 T cell responses. Nevertheless, we cannot exclude that vaginal NKp46 + Eomes -ILC1contribute to this phenotype by the production of helper cytokines. In fact, liver Eomes -ILC1 are described to produce huge amounts of IL-2 upon in vitro or in vivo stimulation, a cytokine known to activate conventional NK cells [28] . Finally, in line with our results, other studies have shown that microbe-infected DC expressing NKG2D ligands are targets of NK cell lysis [54, 55] More, it was also proposed that contaminating NK cells in co cultures between DC and CD4 T cells reduce the ability of vagina-derived DC to prime CD4 T cells [56] . Our data highlight that the fine tune dialog between vaginal ILC and DC, two immune cell types present in the genital tract, impacts the amplitude of mucosal CD8 T cell responses.
In conclusion, our results reveal an unappreciated role of vagina-associated NKp46 + ILC in the regulation of vaccine-induced CD8 responses after local immunization with a subunit vaccine. Determining how to manipulate this regulatory activity at the cellular and molecular levels will help to improve vaccines efficacy. (TIF)
